# **Colgate-Palmolive (India)**

**SELL** 



# **Consumer Staples | Q3FY24 Result Update**

# Margins remain elevated; rich valuation; Downgrade to SELL

- Colgate's Q3FY24 results were ahead of our estimate. Domestic business posted revenue growth of 8.8% YoY. We believe that the volume growth was flattish on a base of 5% de-growth.
- GM expanded by 630bps YoY due to deflation in key RM prices. However, increase in A&P spends restricted EBITDA margins expansion at 560bps.
- Company's focus on driving growth via increasing oral care pie in India through innovation across core categories and developing new segments would remain key growth drivers over the long term. However, increase in competition and better product offerings by competitors like Dabur and Patanjali remains a key challenge. Further, rural slowdown remains challenge for domestic oral care industry.
- As Colgate's Q3 results were a beat, we have upward revised our FY24E EPS by 1.6% at Rs 46.3. However, we have broadly maintained our FY25/26E EPS at Rs 50.3/54.7. We value the stock at 42x FY26E EPS (15% disc to HUL) to arrive at TP of Rs 2,297. Rich valuations, Downgrade to SELL.

#### Results ahead of our estimate

Net revenues increased by 8.1% YoY to Rs 13.9bn. Our analysis suggests that volume growth was flattish on a base of 5% de-growth. GM expanded by 630bps to 72.2%. A 630/90bps decline in RM/other expenses was partially offset by 20/150bps increase in employee cost/A&P spends respectively. Consequently, EBITDA margin expanded by 560bps YoY to 33.6%. EBITDA increased by 29.6% YoY to Rs 4.7bn. APAT increased 35.7% YoY to Rs 3.3bn.

#### **Focused on transforming India's oral care habits**

During the quarter, Colgate MaxFresh was relaunched with a new campaign "NeendBhagaoTaazgiJagao", the campaign presented a new proprietary formula infused with unique cooling crystals to deliver a superior freshness experience, which is outperforming direct competition. Furthermore, the company has continued to endorse its commitment towards improving oral health in India through "The Sweet Truth - Brush at Night" campaign which educates the audience regarding importance of the night time brushing. The advertisement has already reached over 300mn people in urban India.

## Q3FY24 Result (Rs Mn)

Particulars	Q3FY24	Q3FY23	YoY (%)	Q2FY24	QoQ (%)
Revenue	13,957	12,913	8.1	14,711	(5.1)
Total Expense	9,273	9,298	(0.3)	9,890	(6.2)
EBITDA	4,684	3,615	29.6	4,821	(2.8)
Depreciation	414	437	(5.3)	443	(6.6)
EBIT	4,270	3,178	34.4	4,379	(2.5)
Other Income	179	104	71.9	210	(14.9)
Interest	15	13	19.8	11	43.8
EBT	4,434	3,269	35.6	4,578	(3.1)
Tax	1,133	837	35.4	1,178	(3.8)
RPAT	3,301	2,432	35.7	3,401	(2.9)
APAT	3,301	2,432	35.7	3,401	(2.9)
			(bps)		(bps)
Gross Margin (%)	72.2	65.9	631	68.8	341
EBITDA Margin (%)	33.6	28.0	557	32.8	79
NPM (%)	23.7	18.8	482	23.1	54
Tax Rate (%)	25.6	25.6	(5)	25.7	(17)
EBIT Margin (%)	30.6	24.6	599	29.8	83

СМР	Rs 2,536				
Target / Downside	Rs 2,297 / 9%				
NIFTY	21,572				
Scrip Details					
Equity / FV	Rs 272mn / Rs 1				
Market Cap		Rs (	590bn		
		USD	8.3bn		
52-week High/Low	Rs 2,550/ 1,435				
Avg. Volume (no)	405,430				
Bloom Code	CLGT IN				
Price Performance	1M	3M	12M		
Absolute (%)	5	20	69		
Rel to NIFTY (%)	5	11	51		

### **Shareholding Pattern**

	Jun'23	Sep'23	Dec'23
Promoters	51.0	51.0	51.0
MF/Banks/FIs	7.8	5.9	5.9
FIIs	21.8	24.1	24.6
Public / Others	19.4	19.4	19.4

#### Valuation (x)

	FY24E	FY25E	FY26E
P/E	54.8	50.4	46.4
EV/EBITDA	37.0	34.0	31.1
ROE (%)	70.5	70.8	71.2
RoACE (%)	69.5	69.9	70.3

### Estimates (Rs bn)

	FY24E	FY25E	FY26E
Revenue	56.6	60.7	65.3
EBITDA	18.3	19.8	21.5
PAT	12.6	13.7	14.9
EPS (Rs.)	46.3	50.3	54.7

VP - Research: Sachin Bobade Tel: +91 22 40969731 E-mail: sachinb@dolatcapital.com

Associate: Jyoti Amonkar Tel: +9122 61764822 E-mail: jyotia@dolatcapital.com

Associate: Nistha Pala Tel: +9122 40969753

E-mail: nisthap@dolatcapital.com



**Exhibit 1: Actual V/s DART Estimates** 

Particulars (Rs mn)	Actual	Estimates	Variance (%)	Comments
Revenue	13,957	13,429	3.9	Price growth was higher than estimate
EBITDA	4,684	4,390	6.7	GM expansion was higher than estimate
EBITDA margin (%)	33.6	32.7	90bps	
APAT	3,301	3,089	6.9	Cascading effect of higher EBITDA

Source: Company, DART


**Exhibit 2: Change in estimates** 

Doubles (Double)		FY24E			FY25E			FY26E	
Particulars (Rs mn)	New	Old	Chg. (%)	New	Old	Chg. (%)	New	Old	Chg. (%)
Revenue	56,604	57,283	(1.2)	60,719	62,099	(2.2)	65,349	66,816	(2.2)
EBIDTA	18,294	18,027	1.5	19,811	19,806	0.0	21,545	21,539	0.0
EBIDTA margin (%)	32.3	31.5	80bps	32.6	31.9	70bps	33.0	32.2	70bps
PAT	12,598	12,401	1.6	13,678	13,676	0.0	14,874	14,872	0.0
EPS (Rs)	46.3	45.6	1.6	50.3	50.3	0.0	54.7	54.7	0.0

Source: Company DART

We have downward revised our revenue estimates for FY24/25/26E as the volume growth continues to remain muted. However, we have increased our margin estimates for FY24/25/26E to factor in recent price hikes and sharp increase in GM. In line, we have revised our APAT and EPS estimates.

Exhibit 3: Sales Growth (%)




Source: Company, DART

**Exhibit 4: Net Profit Growth (%)** 




Source: Company, DART

Exhibit 5: Gross Margin (%) Trend



Source: Company, DART


Exhibit 6: EBITDA Margins Trend (%)



Source: Company, DART




# Exhibit 7: A&P Spends (% Of Revenues)



Source: Company, DART

# Exhibit 8: Volume growth overall (% YoY)



Source: Company, DART



# **Financial Performance**

# **Profit and Loss Account**

(Rs Mn)	FY23A	FY24E	FY25E	FY26E
Revenue	52,262	56,604	60,719	65,349
Total Expense	36,792	38,310	40,908	43,803
COGS	17,942	17,564	18,731	20,040
Employees Cost	3,770	3,970	4,137	4,322
Other expenses	15,080	16,776	18,040	19,442
EBIDTA	15,470	18,294	19,811	21,545
Depreciation	1,748	1,841	1,966	2,092
EBIT	13,722	16,453	17,845	19,453
Interest	49	100	100	100
Other Income	536	720	817	860
Exc. / E.O. items	(112)	0	0	0
EBT	14,097	17,074	18,562	20,213
Tax	3,625	4,476	4,884	5,339
RPAT	10,472	12,598	13,678	14,874
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	10,584	12,598	13,678	14,874
Balance Sheet (Rs Mn)	FY23A	FY24E	FY25E	FY26E
Sources of Funds				
Equity Capital	272	272	272	272
Minority Interest	0	0	0	0
Reserves & Surplus	16,892	18,282	19,792	21,434
Net Worth	17,164	18,554	20,064	21,706
Total Debt	690	690	690	690
Net Deferred Tax Liability	(288)	(288)	(288)	(288)
Total Capital Employed	17,565	18,956	20,465	22,107
Applications of Funds				
Net Block	8,618	8,277	7,811	7,219
CWIP	1,141	1,141	1,141	1,141
Investments	0	0	0	0
Current Assets, Loans & Advances	18,783	23,993	26,871	30,109
Inventories	3,355	3,694	3,962	4,264
Receivables	1,574	1,460	1,566	1,685
		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4	40440

9,230

4,625

10,976

7,611

3,365

7,806

17,565

0

14,283

4,556

14,455

8,244

6,212

9,537

18,956

0

16,695

4,647

15,357

8,843

6,514

11,513

20,465

0

19,410

4,750

16,362

9,517

6,845

13,747

22,107

0

**Total Assets** E – Estimates

**Payables** 

Cash and Bank Balances

Other Current Liabilities

**Net Current Assets** 

**Less: Current Liabilities & Provisions** 

Loans and Advances

Other Current Assets

sub total



Particulars	FY23A	FY24E	FY25E	FY26E
(A) Margins (%)				
Gross Profit Margin	65.7	69.0	69.2	69.3
EBIDTA Margin	29.6	32.3	32.6	33.0
EBIT Margin	26.3	29.1	29.4	29.8
Tax rate	25.7	26.2	26.3	26.4
Net Profit Margin	20.0	22.3	22.5	22.8
(B) As Percentage of Net Sales (%)				
COGS	34.3	31.0	30.8	30.7
Employee	7.2	7.0	6.8	6.6
Other	28.9	29.6	29.7	29.8
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	279.5	164.5	178.4	194.5
Inventory days	23	24	24	24
Debtors days	11	9	9	9
Average Cost of Debt	6.5	14.5	14.5	14.5
Payable days	53	53	53	53
Working Capital days	55	62	69	77
FA T/O	6.1	6.8	7.8	9.1
(D) Measures of Investment	V	0.0	,,,	J
AEPS (Rs)	38.9	46.3	50.3	54.7
CEPS (Rs)	45.3	53.1	57.5	62.4
DPS (Rs)	38.9	41.2	44.7	48.6
Dividend Payout (%)	99.9	89.0	89.0	89.0
BVPS (Rs)	63.1	68.2	73.8	79.8
RoANW (%)	60.7	70.5	70.8	71.2
RoACE (%)	59.8	69.5	69.9	70.3
RoAIC (%)	146.0	253.0	422.7	601.6
(E) Valuation Ratios				
CMP (Rs)	2536	2536	2536	2536
P/E	65.2	54.8	50.4	46.4
Mcap (Rs Mn)	689,846	689,846	689,846	689,846
MCap/ Sales	13.2	12.2	11.4	10.6
EV	681,306	676,253	673,841	671,126
EV/Sales	13.0	11.9	11.1	10.3
EV/EBITDA	44.0	37.0	34.0	31.1
P/BV	40.2	37.2	34.4	31.8
Dividend Yield (%)	1.5	1.6	1.8	1.9
(F) Growth Rate (%)				
Revenue	2.5	8.3	7.3	7.6
EBITDA	(1.2)	18.3	8.3	8.8
EBIT	(1.2)	19.9	8.5	9.0
PBT	0.1	21.1	8.7	8.9
APAT	(1.8)	19.0	8.6	8.7
EPS	(1.8)	19.0	8.6	8.7



(1,500)

(1,500)

Cash Flow				
Particulars	FY23A	FY24E	FY25E	FY26E
Profit before tax	14,209	17,074	18,562	20,213
Depreciation & w.o.	1,748	1,841	1,966	2,092
Net Interest Exp	49	100	100	100
Direct taxes paid	(3,809)	(4,476)	(4,884)	(5,339)
Change in Working Capital	(89)	3,322	436	481
Non Cash	(851)	0	0	0
(A) CF from Operating Activities	11,257	17,861	16,180	17,547
Capex {(Inc.)/ Dec. in Fixed Assets n WIP}	(642)	(1,500)	(1,500)	(1,500)
Free Cash Flow	10,616	16,361	14,680	16,047
(Inc)./ Dec. in Investments	619	0	0	0
Other	1,262	0	0	0

Closing Cash balances	9,230	14,283	16,695	19,410
Opening Cash balances	7,547	9,230	14,283	16,695
Net Change in Cash	1,683	5,053	2,412	2,715
(C) CF from Financing	(10,814)	(11,308)	(12,268)	(13,332)
Other	0	0	0	0
Dividend Paid (Incl. Tax)	(10,575)	(11,208)	(12,168)	(13,232)
Interest exp net	(49)	(100)	(100)	(100)
Inc./(Dec.) in Debt	(191)	0	0	0

1,240

0

(1,500)

Closing Cash balances
E – Estimates

(B) CF from Investing Activities

Issue of Equity/ Preference

Notes



# **DART RATING MATRIX**

**Total Return Expectation (12 Months)** 

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

# **Rating and Target Price History**



Month	Rating	TP (Rs.)	Price (Rs.)
Jan-23	Reduce	1,492	1,459
May-23	SELL	1,543	1,628
Jul-23	Accumulate	2,113	1,884
Oct-23	Reduce	2,113	2,034

<sup>\*</sup>Price as on recommendation date

# **DART** Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747		
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745		
CONTACT DETAILS					
Equity Sales	Designation	E-mail	Direct Lines		
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709		
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735		
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779		
Girish Raj Sankunny	VP - Equity Sales	girishr@dolatcapital.com	+9122 4096 9625		
Pratik Shroff	AVP - Equity Sales	pratiks@dolatcapital.com	+9122 4096 9621		
Rajeev Lala	AVP - Equity Sales	rajeevl@dolatcapital.com	+9122 4096 9767		
Equity Trading	Designation	E-mail			
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728		
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707		
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702		
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715		
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705		



#### Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

#### II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. persons only: This research report is a product of Dolat Capital Market Private Limited, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.



## **Dolat** Capital Market Private Limited.

Corporate Identity Number: U65990GJ993PTC116741
Member: BSE Limited and National Stock Exchange of India Limited.
SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000014012

Regd. office: 1401-1409, Dalal Street Commercial, Block 53 (Bldg. No.53E) Zone-5, Road-5E, Gift City, Sector 9, Gandhinagar-382355 Gujarat, India.

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com